The similar proteomic alterations induced by bortezomib in both cell lines suggest that these baseline differences and especially BCL-2 family protein levels contribute to the blunted myeloma sensitivity to proteasome inhibition as well as dexamethasone and BH3 mimetics. The gene discussed is BCL2; the disease is plasma cell myeloma.